Mallinckrodt Pharmaceuticals Blog

Kratom.org - Kratom Strains & Vendors Reviewed

Skip to content
  • Home
  • Achievements
  • Advocacy
  • Culture
  • History
  • Philanthropy
  • Website

Advocacy

The Patient Safety Initiative

  • by Brendan Boylan
  • Posted on June 25, 2019June 23, 2019
  • Advocacy

Mallinckrodt partners with the Patient Safety Movement Foundation to help eliminate preventable deaths in hospitals Medical errors are now the third leading cause of death in the United States According to the Institute of Medicine, […]

Read More

Mallinckrodt Supports LGBTQ Pride Celebration in New Jersey

  • by Brendan Boylan
  • Posted on June 23, 2019
  • Advocacy

Mallinckrodt showed its support for the lesbian, gay, bisexual, transgender and queer (LGBTQ) community, taking part in the 28th annual LGBTQ Pride Celebration in Asbury Park, NJ on June 2. More than 50 people participated, […]

Read More

Supporting Awareness for Autoimmune Diseases in May

  • by Brendan Boylan
  • Posted on May 28, 2019
  • Advocacy

Autoimmune diseases like rheumatoid arthritis and lupus are a major cause of chronic illness and disability in the United States and elsewhere. They occur when the body’s immune system, which normally fights off bacteria and […]

Read More

Mallinckrodt Establishes Uveitis Research Fellowship

  • by Brendan Boylan
  • Posted on April 2, 2019September 18, 2019
  • Advocacy

As a company committed to managing complexity to help advance treatments for critical and severe illnesses like uveitis, we’re proud to support research of inflammatory eye disorders in partnership with the Association for Research in […]

Read More

Posts navigation

Older posts
Newer posts
  • NICU Awareness Month: Experts Share Advice on What to Expect in the NICU

    September 30, 2020
  • Mallinckrodt Volunteers Assemble and Distribute PPE for the St. Louis Community

    August 19, 2020
  • MNK CEO Mark Trudeau on the Value of an Inclusive Workplace

    June 30, 2020
  • An Open Letter from Mallinckrodt CEO Mark Trudeau on Diversity and Inclusion

    June 3, 2020
  • Creating a sense of community during times of isolation: Patient advocacy groups respond to the COVID-19 crisis

    May 29, 2020

Featured Video

Categories

  • Achievements
  • Advocacy
  • Culture
  • History
  • Media
  • Philanthropy
  • Uncategorized

Latest Posts

NICU Awareness Month: Experts Share Advice on What to Expect in the NICU

Mallinckrodt Volunteers Assemble and Distribute PPE for the St. Louis Community

MNK CEO Mark Trudeau on the Value of an Inclusive Workplace

An Open Letter from Mallinckrodt CEO Mark Trudeau on Diversity and Inclusion

Creating a sense of community during times of isolation: Patient advocacy groups respond to the COVID-19 crisis

Subscribe via Email

Enter your email address to subscribe and receive notifications of new posts by email.

About Mallinckrodt Pharmaceuticals

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.

Visit Our Corporate Website

About Us

Products

Core Strengths

Corporate Social Responsibility

Investor Relations

Careers

Connect & Share

RSS
LinkedIn

Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company. © 2015 Mallinckrodt.

Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.